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Edward Jenner, was an English surgeon, who is credited 
with creating the first vaccine, in 1798, which was used 
to combat the Smallpox virus. Jenner employed the 
zoonotic Cowpox virus (as a live vaccine). Using the 
observation that milkmaids were somehow protected 
against Smallpox, he hypothesized that the pus from the 
milkmaid’s skin blisters could be used as a vaccine to 
inoculate other people, to protect against Smallpox. His 
successful clinical trial, of 23 patients, ultimately led the 
English Parliament to pass the Vaccination Act in 1840, 
making vaccination a new public health policy. His 
approach was used all over the world and ultimately led 
to the eradication of Smallpox by the WHO (World 
Health Organization) in 1980, nearly 40 years ago.  
 
What can we learn today from Jenner’s observations 
that could be useful for designing a vaccine against 
SARS-CoV-2? Are there any less pathogenic viruses 
that could be used as a vaccine against SARS-CoV-2? 
The answer is probably yes.  
 
For example, there are four human coronaviruses that 
are known to cause the common cold, namely 229E, 
NL63, OC43, and HKU1, which lead to mild upper 
respiratory infections (URI’s) [1–4]. According to the 
CDC, their route of transmission appears to be similar 
to SARS-CoV-2, but the onset of symptoms is quite 
mild in comparison. https://www.cdc.gov/coronavirus/ 
general-information.html  
 
All five viruses contain a viral spike glycoprotein 
(VSG), which is the main target of SARS-CoV-2 
vaccine development world-wide.  
 
One attractive hypothesis is that inoculation with the 
common cold coronavirus (229E, NL63, OC43, or 
HKU1) or, more likely, an attenuated version, could 
provide immunity against SARS-CoV-2. If that was the 
case, then we might already have a naturally-occurring 
vaccine at hand, that could soon be implemented, off the 
shelf. 
 
To begin to test this hypothesis, we retrieved the protein 
sequences of the relevant viral spike glycoproteins from 
a variety of available databases, such as UniProt/ 
FASTA, and analysed their shared protein sequence 
similarity and identity using BLASTP.  
 
Table 1 summarizes the results of this brief analysis. 
 
Based on this simple analysis, the viral spike 
glycoprotein of coronavirus OC43 appears to be the 
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ABSTRACT 
 
Three recent papers published in Nature, Science and Cell, all present clear evidence that there is cross-reactive 
T-cell immunity between human coronaviruses (229E, NL63, OC43, and HKU1), linked with the common cold, 
and SARS-CoV-2, the causative agent of COVID-19. Can we use this information to design and build a new 
vaccine based on the less pathogenic, common cold coronaviruses, for the prevention of COVID-19? If we look 
at the history of medicine and vaccine development, from the point of view of Edward Jenner, the answer just 
might be yes. 
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Table 1. Protein sequence identity of the viral spike glycoproteins of  
SARS-Cov-2 and the common cold corona viruses (229E, NL63, OC43,  
or HKU1). 
Common Cold VSG SARS-Cov-2 VSG 
229E 27.78% 
NL6 31.27% 
OC43 37.65% 
HKU1 36.66% 
 
most similar to that of SARS-CoV-2, with nearly 38% 
identity and up to 53% similarity (Figure 1). In fact, the 
viral spike glycoproteins of coronavirus OC43 and 
HKU1 are also quite similar to each other, sharing 64% 
identity (Figure 2). So, both OC43 and HKU1 would 
possibly be good candidates for developing a potential 
vaccine to SARS-CoV-2. 
 
Is there any clinical evidence to support these 
assertions?  
 
 
 
Figure 1. Protein sequence alignments of the Viral Spike Glycoproteins (VSGs) from SARS-CoV-2 and the related Human 
Coronavirus OC43. Areas of high sequence homology are highlighted in color, which may represent potentially shared epitopes for immune 
recognition. Generated using the online program BLASTP, by pairwise sequence analysis. 
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Figure 2. Protein sequence alignments of the Viral Spike Glycoproteins (VSGs) from two related Human Coronaviruses, 
namely OC43 and HKU1. Note the high homology between OC43 and HKU1, with up to 78% similarity. Generated using the online 
program BLASTP, by pairwise sequence analysis. The same potentially shared epitopes, highlighted in color in Figure 1, are also highlighted 
here, for comparison. 
www.aging-us.com 18800 AGING 
Three recent papers published in Nature, Science and 
Cell have begun to look at the existence of cross-
reactive immunity in a variety of patient populations, 
especially patients infected with the SARS-CoV-2 
(with frank COVID-19 or asymptomatic) and 
uninfected patients. The results are all quite 
encouraging, directly demonstrating cross-reactive T-
cell immunity between SARS-CoV-2 and the existing 
known human cold coronaviruses (229E, NL63, OC43, 
and HKU1) [5–7]. One of the papers also detected 
cross-reactive serum IgG as well.  
 
These reports clearly provide tantalizing clinical 
evidence for the feasibility of using a human cold 
coronavirus, such as attenuated OC43 or HKU1, as a 
potential vaccine for the prevention of COVID-19. 
What would Edward Jenner suggest, if he was living 
today? 
 
Further support for this idea has recently appeared in 
the popular press and was supported by data from the 
National Institutes of Health (NIH), because there is 
significant shared serological cross-reactivity between 
SARS-CoV-2, OC43 and HKU1 [8, 9].  
 
Fortunately, two live coronaviruses, OC43 and 229E, 
associated with the common cold, are actually 
commercially available from the American Type Culture 
Collection (ATCC), which could greatly facilitate their 
potential use in new, off-the-self, vaccine development.  
https://www.lgcstandards-atcc.org/products/all/VR-
1558.aspx  
https://www.lgcstandards-atcc.org/products/all/VR-
740.aspx  
 
Moreover, the VSGs from OC43 and HKU1, may also 
be sufficient to convey cross-reactive immunity, when 
recombinantly-inserted in another non-pathogenic viral 
vector, specifically designed for live or attenuated 
vaccine immunizations (Figure 3). 
 
Ultimately, this may be a safer approach, than using the 
VSG from SARS-CoV-2, which may have mild 
negative, or even pathogenic, side-effects.  Only time 
will tell.  
 
Nature may have already done the “experiment” or 
“clinical trial” for us, as so many people that are SARS-
CoV-2 virus-positive, are asymptomatic and show 
evidence of cross-reactive immunity, to both SARS-
CoV-2 and the common cold coronaviruses.  
 
These findings have been independently confirmed 
now, in several different laboratories world-wide. 
 
 
 
Figure 3. Schematic diagram summarizing the possible use of Human Coronaviruses that cause the common cold as 
naturally-occurring vaccines for targeting SARS-CoV-2 and preventing COVID-19. A brief flow-diagram is presented, outlining a 
vaccine development strategy. 
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UNIPROT accession numbers for 5 relevant protein 
sequences: 
 
P0DTC2,  
SPIKE_SARS2 Spike glycoprotein, Severe acute 
respiratory syndrome coronavirus 2 
https://www.uniprot.org/uniprot/P0DTC2.fasta 
 
Q6TUL7,  
CVH22 Spike glycoprotein Human coronavirus 229E 
https://www.uniprot.org/uniprot/Q6TUL7.fasta 
 
Q6Q1S2, 
SPIKE_CVHNL Spike glycoprotein Human coronavirus 
NL63 
https://www.uniprot.org/uniprot/Q6Q1S2.fasta 
 
P36334,  
SPIKE_CVHOC Spike glycoprotein Human coronavirus 
OC43 
https://www.uniprot.org/uniprot/P36334.fasta 
 
Q0ZME7, 
SPIKE_CVHN5 Spike glycoprotein Human coronavirus 
HKU1 
https://ebi10.uniprot.org/uniprot/Q0ZME7.fasta 
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SUPPLEMENTARY MATERIALS 
 
Note Added in Proof 
 
After this Perspective Article was submitted for peer-
review, another relevant paper appeared in the British 
Medical Journal (BMJ), highlighting the role of human 
coronaviruses associated with the common cold in 
conferring cross-reactive immunity to SARS-CoV-2 in 
the world population.  
https://www.bmj.com/content/370/bmj.m3563.full 
 
 
Doshi P. Covid-19: Do many people have pre-existing 
immunity? The British Medical Journal. 2020; 
370:m3563. 
 
